solid fundament hope better entri
initi coverag argenx neutral rate target price argx strong
perform past two year reflect heighten expect believ
argx promis asset solid fundament estim current valuat alreadi
reflect substanti credit lead asset efgartigimod cusatuzumab would
select entri point
efgartigimod potenti platform within product efgartigimod reduc amount
igg autoantibodi circul offer altern broad immunosuppress
agent ivig/plex asset emerg potenti best-in-class agent
potenti fcrn antagonist class earli evid efgartigimod may
differenti amen safeti profil competit efficaci howev
fcrn antagonist market highli competit remain earli day see phase
data gmg key catalyst potenti unlock option valu
interim news flow competitor may carri neutral neg reward/risk
argx share current valuat evid best-in-class subcutan
formul may help determin long-term competit class expect
data enhanz formul
catalyst month evolv fcrn antagonist race
pay attent data alexion potenti competit
sc product data nipocalimab momenta gmg well
potenti updat immunov gmg studi
partner cusatuzumab program diversifi risk cusatuzumab first-in-class
antibodi target demonstr high respons rate small studi
aml orr patient cr/cri regard physician
spoke one promis pipelin agent indic subsequ
partnership favor term serv valid
drug potenti janssen guid possibl peak sale potenti north
valuat risk target price base dcf project
competitive/commerci headwind financ risk potenti
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
argenx se biotechnolog compani develop antibody-bas
therapi treatment autoimmun diseas cancer
product includ efgartigimod treatment autoimmun diseas
cusatuzumab treatment aml
blue sky valuat base posit phase gmg
readout efgartigimod po de-risk addit
efgartigimod indic itp/pv po
 weigh
grey sky valuat base unexpect safeti issu
render efgartigimod uncompetit po efgartigimod
program weigh
 close
tabl content
debat expect pushback
efgartigimod front-runn potenti multi-billion dollar therapeut class
commerci opportun fcrn antagonist class
one-trick poni cusatuzumab pipelin partnership
valuat risk
initi coverag argenx argx neutral rate target price
compani outperform nasdaq biotechnolog index nbi recent year
posit clinic updat greater awar around neonat fc receptor fcrn
antagonist class believ argx promis asset solid fundament think
current valuat alreadi reflect substanti credit efgartigimod cusatuzumab
would select entri point
efgartigimod compani lead wholly-own asset emerg possibl best-in-class
agent earli day develop rel crowd fcrn antagonist class
efgartigimod reduc amount igg autoantibodi circul offer altern
broad immunosuppress agent immunoglobulin infus ivig /plasma exchang plex
see earli evid efgartigimod may amen safeti profil
competit efficaci fcrn program develop
project combin peak revenu potenti efgartigimod gener
myasthenia gravi gmg idiopath thrombocytopen purpura itp believ
fcrn class carri potenti though target indic
becom increasingli competit see phase data gmg key catalyst
potenti unlock option valu de-risk indic chronic
inflammatori demyelin polyneuropathi cidp pemphigu vulgari pv among other
interim news flow competitor may carri neutral neg reward/risk argx
share current valuat believ evid best-in-class subcutan sc
formul efgartigimod crucial determin long-term competit flexibl
across indic expect data enhanz sc formul ye
could offer higher convict floor valu efgartigimod
cusatuzumab first-in-class antibodi target demonstr high respons rate
small studi acut myeloid leukemia aml overal respons rate orr
patient complet remiss cr complet remiss incomplet
hematolog recoveri highlight physician spoke one
promis pipelin agent indic earli data contribut valuabl strateg
allianc janssen pharmaceut up-front payment mileston double-digit
royalti ou us econom see favor term
early-stag asset import extern valid potenti janssen also
highlight cusatuzumab potenti
argx innov access program antibodi develop expertis yield sever
first-in-class asset potenti best-in-class featur compani recent disclos
two addit wholly-own asset addit four partner program though
visibl addit upsid stock agent limit point
arriv target price use blend valuat approach includ
product-bas dcf estim a/effici dcf dcf model assum discount
rate fulli dilut share million risk includ clinical/regulatori updat
competitive/commerci headwind financ risk potenti
credit suiss biotech short-term argx outlook believ evid competit
subcutan formul data ye efgartigimod crucial
differenti asset across competit fcrn landscap clear path forward pv
updat data could sourc upsid expect remain fairli low
increment updat fcrn program could help de-risk class
think posit outcom alreadi reflect stock price
credit suiss biotech long-term argx outlook see gmg
readout key clinic catalyst confirm efgartigimod potenti across autoimmun
indic cusatuzumab develop strategi may potenti sourc upsid argx
credit suiss biotech argx outlook longer term see argx potenti
emerg one attract target within coverag univers expect
multipl larg biotech/pharma compani may interest fcrn class expect
broad util met shorter term deal seem less like consid limit long-term
dose safety/efficaci data efgartigimod still uncertain differenti pictur
debat expect pushback
stock strong perform past coupl year still
room upsid much depend prospect materi
potenti ye could still room upsid though think expect bake
stock current fairli high expect stock remain somewhat range-bound
investor visibl fcrn class evolv current market cap
think stock price substanti commerci opportun limit risk
efgartigimod gmg autoimmun indic cusatuzumab aml
think expect built name could see multipl potenti
buyer favor posit fcrn asset class potenti though
would expect transact depend data gmg clearer pictur
safeti toler mechan action moa improv visibl fcrn
develop competit
subcutan formul think argx could attract acquisit target space
valuat number competit agent class make difficult high
convict thesi short term
landscap strong prospect
stage think stock could offer interest long-term invest opportun
key factor efgartigimod maintain lead remain competit
long term
current see efgartigimod potenti best-in-class asset fcrn antagonist class
think that alreadi reflect current stock price actual amount clinic data
compound fcrn space somewhat limit believ difficult
high convict rel market posit among competitor potenti opportun
differ class indic point news flow next month see
figur help clarifi current unknown
hv enhanz efgartigimodscostart itp efgartigimod ivostart cidp efgartigimod ivodata itp roza sc updat ostart itp roza scodata pv efgartigimod ivodata hv gmg efgartigimod ivostart gmg scodata gmg roza scodata cidp roza scodata go scodata go waiha ivodata gmg nipo ivodata waiha nipo ivodata hdfn nipo ivodata scodata waiha sclegend alexion nipocalimab nipo ucb charl martineau pm univers toronto novemb
figur fcrn antagonist expect readout
import factor efgartigimod remain lead fcrn class
safety/toler profil success develop subcutan formul
allow infrequ small-volum dose
toler efgartigimod shown potenti favor differenti
competitor far lot emphasi differenti
bull name mechanist reason case still somewhat
specul base small sampl sizes/limit dose period product
relev clinic import featur debat modest
toler differenti may crucial factor determin long-term
competit class
subcutan formul competit agent class oral sc
infrequ iv dose well progress sc fcrn antagonist put pressur
argx develop competit sc formul efgartigimod think
efgartigimod design certainli advantag versu full-length monoclon antibodi
race compani current pursu develop two sc formul
one develop potenti mainten product expect go trial
itp develop enhanz technolog design
non-inferior potenti interchang iv formul beyond offer
option patient altern formul may enabl compani explor
differ formulations/pr structur across indic think compani well
posit landscap would like greater visibl expect product
profile/dos regimen addit valid induct follow lower-dos
mainten strategi certain indic player develop sc formul
 ucb immunov alexion nipocalimab momenta offer potenti
short iv infus min less potenti
hv enhanz efgartigimodscdevelop attract sc formul crucial determin competit class long run look non-inferior iv flat dose volum allow simpl sc push pump odata pv efgartigimod ivupd data cohort look speed onset sustain diseas control go-forward strategi program studi also offer insight safety/toler prolong dose period odata hv time well see data human candid focu immunogen igg lower vs dose regimen expect data support less frequent sc small volum inject odata gmg efgartigimod ivw limit inform baselin dose regimen analyz total data would ideal like see pbo-adjust benefit point mg-adl benefit activ arm would like see support qmg trend respond basi improv mg-adl look pbo-adjust rateid would like see mainten dose less frequentsafety/toler profil similar seen date odata gmg roza pbo-control trial help determin rel competit posit provid much larger sampl size determin tolerability/safeti differenti odata cidp roza sclike first poc readout indic readthrough argx odata go scodata go data patient new indic class odata gmg nipo ivthi studi gmg nipo dose iv like final data point gmg ahead argx waiha nipo ivodata hdfn nipo ivodata scsmall pbo-control studi offer anoth data point potenti valid class gmg odata waiha scfirst robust dataset indic readthrough mnta legend alexion nipocalimab nipo ucb charl martineau pm univers toronto
final see increment valu first-to-market indic
howev intuit mechan action class potenti substanti
read-through even healthi volunt studi creat reason chanc agent
rapidli catch event differenti end modest among two three
asset within class
initi fcrn indic crowd
possibl continu see potenti room increment growth space new
moa explor report titl someth get ger
autoimmune/inflammatori market continu grow across number major biolog
market patient often fail achiev sustain respons cycl across differ
drugs/moa think fcrn antagonist carv share indic
develop though physician spoken see limit role class
consid potenti price constraint across indic avail treatments/emerg
mechanisms/drug develop complement inhibitor gmg oral tpo btk
inhibitor itp etc think clinic data date strongli suggest proof-of-concept
poc indic though believ current avail dataset put fcrn
antagonist clear lead efficaci durat respons gener
conserv consensu size opportun long-term share
product candidateefgartigimod rozanolixizumabnipocalimab fc-fragmentabdeg mutationhuman mabhuman agli mabhuman mabsmal protein kda human mab agli adcc mutant sc formulationenhanz develop expect non-inferior iv allow small sc push data formul compani develop weekli ml subcutan mainten inject efgartigimod develop sc formul deliveri weekli self-administ sc infus dose pump develop stabl high-concentr subcu formul expect low-volum administr goal avail launch product mg data expect sc formul develop expect small volum sc inject dose weekli less often potenti data expect develop sc formul administ weekli sc inject plan explor mainten charl martineau pm univers toronto novemb
efgartigimod front-runn potenti
efgartigimod human antibodi fragment fc fragment leverag natur fc-fcrn
interact increas igg antibodi clearanc potenti serv therapeut option
sever autoimmun diseas base data date believ efgartigimod potenti
best-in-class featur among fcrn antagonist though long-term competit within
class determin
neonat fc receptor fcrn antagonist reduc amount igg autoantibodi
circul offer altern broad immunosuppress agent ivig/plex
believ fcrn antagonist class may rang though
target indic becom increasingli competit
efgartigimod design leverag biolog natur ligand fcrn could
translat differenti safeti efficaci compar agent fcrn
antagonist class see earli clinic evid point amen safeti profil
competit efficaci efgartigimod though acknowledg field earli
see combin peak revenu potenti efgartigimod gmg itp phase
data gmg could unlock substanti upsid potenti option
de-risk indic cidp pv among other though believ current stock
price level reflect commerci opportun limit clinic risk
fcrn antagon therapeut approach
antibodi also call immunoglobulin ig protein produc immun system
help neutral foreign particl like microorgan virus bind particl
recruit immun respons five antibodi class isotyp igg
iga igm igd ige differ structur function igg isotyp
abund antibodi type circul
autoimmun diseas often caus
autoantibodi current standard care
carri sever limit high unmet
need safe efficaci therapeut
figur igg antibodi account circul antibodi
rich clinic immunolog principl practic st loui mo mosby/elsevi
autoimmun diseas often caus presenc antibodi attack healthi
cells/tissu bodi pathogen autoantibodi may affect sever part bodi
differ patholog therapeut approach condit usual reli
strategi reduc autoantibodi product increas autoantibodi clearanc
broadli immunosuppress agent corticosteroid immunomodul drug promot
destruct nativ b-cell produc antibodi rituximab immunoglobulin infus
ivig /plasma exchang plex often employ across sever autoimmun
indic vari degre success
sever drawback strategi advers event prolong exposur
corticosteroids/immunomodul common b-cell ablat reduc circul
antibodi type autoantibodi ivig therapi could requir high dose may
limit durat respons addit shortages/qu issu past
new therapeut option need autoimmun diseas fcrn antagonist offer
promis approach igg-medi diseas
fcrn antagonist potenti address
sever igg-medi autoimmun diseas
autoantibodi believ class
potenti broadli reliabl util
altern immunosuppress regimen
fcrn promis autoimmun diseas
neonat fc receptor fcrn broadli express vascular endothelium thin
membran line insid blood vessel shown involv sever
process relat igg antibodi includ
rescu igg antibodi lysosom degrad
igg transport mucos surfac
igg transcytosi type transport across interior cell across tissu cell
re-adsorpt igg antigen complex antigen present region lymphoid
shown figur fcrn respons recycl igg antibodi interact
fc region antibodi account extend half-lif rel isotyp
key featur fc-fcrn interact ph depend fc region
antibodi bind high affin fcrn neonat fc receptor acid ph
physiolog ph
figur fcrn respons long half-lif igg antibodi
sever compani current develop product candid interfer natur
recycl function fcrn way reduc circul concentr autoantibodi
igg subtyp potenti allevi autoimmun diseas symptom approach valid
ivig plex
sever possibl way interfer fcrn-igg interact includ
satur fcrn non-pathogen igg believ benefit seen
immunoglobulin infus across sever indic least part driven
block fcrn-igg interact monoclon antibodi peptid small molecul
outcompet nativ igg bind fcrn util recombin igg higher affin
protein includ igg antibodi uptak endosom igg antibodi may bind fcrn ph proteins/antibodi degrad enzym igg releas back circul ph charl martineau pm univers toronto novemb
interf fcrn-igg interact number fcrn-unbound antibodi higher
increas overal clearanc igg antibodi regular pathogen result
direct reduct pathogen autoantibodi shown potenti
benefici sever indic human anim model
soon crown winner earli evid
suggest efgartigimod may emerg
what uniqu efgartigimod fcrn antagonist clinic full-length
immunov efgartigimod human fc fragment specif
mutat reduc fcr bind featur offer sever point potenti
differenti across landscap
efgartigimod hijack fcrn bind site sinc fc region natur ligand antibodi
develop bind fcrn receptor leav fc region antibodi expos
potenti promot antibody-depend cellular cytotox complement activ
though product clinic taken differ approach minim potenti
problem contrast efgartigimod buri within receptor avail fcr
mediat signal could account amen safeti profil seen clinic
efgartigimod retain ph-depend bind featur least partial recycl
natur fcrn mechan translat increas half-lif compar
antibodi potenti sustain pharmacodynam pd profil
featur along smaller size also contribut greater tissu distribut antibodi
bind fcrn may actual direct receptor lysosom degrad
efgartigimod higher volum distribut compar full-length antibodi
candid could translat differenti efficaci certain indic
efgartigimod uniqu design rel
agent class emerg
front-runn efgartigimod largest
fcrn
antagonist date earli data suggest
tolerability/safeti
competit efficaci though still
earli day class
better
efgartigimod also establish healthi volunt across indic igg lower
potenti clinic across igg subtyp without impact immunoglobulin albumin
agent fcrn antagonist class also demonstr igg lower activ
earli clinic data gmg itp suggest potenti efficaci differenti favor efgartigimod
rel roza also see efficacy/safeti balanc potenti favor efgartigimod
agent clinic
efgartigimod appear cleanest toler profil class fcrn
class still earli day limit exposur patient date base
studi healthi volunt efgartigimod seem amen safeti profil
compar favor competitor class could differenti factor
commerci expect multipl agent eventu make market
charl martineau pm univers toronto figur efgartigimod earli data suggest potenti best-in-class profil
argenxucbimmunovantalexionefgartigimod rozanolixizumabnipocalimab fc-fragmentabdeg mutat doesnt engag fc receptor human mabhuman agli mabhuman mab agli adcc mutant human mabsmal protein kda ph nm nmph nm nm igg reduct achiev week maximum reduct last dose igg level remain reduc period week return baselin month igg concentr serum reduc singl ascend dose demonstr dose respons igg reduct multi-dos level achiev sustain receptor occup mean igg reduct na total igg reduc dose-depend manner mg/kg dose group day post-dos na sc formul steadi state igg reduct achiev weekli dose mg fix dose sc rout administr rozanolixizumab human demonstr favor safeti toler profil iv rout na averag reduct follow singl sc dose mg averag maximum reduct mg weekli sc cohort averag maximum reduct mg weekli sc cohort na nasafety/toler volunt mad activ vs pbo sad activ vs pbomd vs pboactiv na pt report teae nanausea sad iv sc pbo nausea iv sc pbo diarrhea iv sc pbo nausea mad activ vs pbonausea pbo diarrhea pbo na na limit number sampl activ pbo posit ada titer signal typic detect limit assay found studi subject adaposit subject detect across rozanolixizumab treatment group iv sc howev detect ada limit quantif assay observ five subject sad subject subject posit neutral antibodymd four subject one placebo-tr subject four md subject neutral antibodi posit sad subject sad portion test posit low level ada subject test posit ada baselin md preliminari analysi mad subject develop confirm ada last sampl timepoint week last dosena naon sae hyperventil report consid unlik relat studi drug efgartigimod-rel sae ae lead discontinu treatment report sever te headach back pain report four subject roza iv group sc rout administr roza favor safeti toler profil iv rout sever te seriou one subject experienc transient elev alanin aminotransferas two report neither consid relat studi drugon teae headach sever grade report grade te seriou nano signific decreas albumin serum levelsmodest decreas mean albumin concentr time iv sc stat-sig differ pbo valu remain within normal reduct day depend albumin reduct mg cohort mg cohort effect observ serum concentr albumin naaddit findingsimpact albumincompanyheadachegi disordersadaaffinitybindingdesignproduct candidateigg lower charl martineau pm univers toronto novemb
commerci opportun
extens list autoimmun indic like igg-medi would
possibl amen fcrn antagon figur date clinic develop
emphas indic clearer correl pathogen igg
lower diseas improv believ proven safe chronic use potenti
overal class signific opportun across indic peak
base rough estim five near term indic explor upsid
potenti expand addit diseas area howev first wave
indic becom increasingli competit actual uptak fcrn antagonist
point debat
figur sever autoimmun diseas thought igg-medi
tam
opportun class dont expect fcrn
antagonist restrict ivig switch
physician spoke excit fcrn antagonist class prospect
see potenti address multitud indic key draw agent
develop physician cite sever autoimmune/inflammatori drug potenti comp
broad util across indic see substanti potenti class howev
less bullish indic see fcrn antagonist mostli altern
ivig potenti limit role indic given treatment option current
indic market ripe share captur
view fcrn antagonist broad potenti applic across autoimmun diseas
fcrn agent seen investor potenti replac immunoglobulin
therapi iv sc well util ivig comprehens term commonli util therapeut
approach autoimmun diseas sinc share common mechan action
lower monoclon antibodi
global immunoglobulin market estim per day argenx
 day global ig volum indic grow similar figur
disclos argenx estim global market grow compound-annual-growth-rate
neurolog repres market
neurologyhematologydermatolog cidp waiha pemphigu myasthenia gravi mg itp bullou pemphigoid guillian-barr syndrom anti-phospholipid syndrom dermatomyos neuromyel optica scleroderma anti-nmda epidermolysi bullosa acquisitanephrologyrheumatologyoth membran nephropathi rheumatoid arthriti hemolyt diseas fetus/newborn lupu nephriti system lupu erythematosu grave ophthalmopathi anca vasculitisindicationaprox preval us eu address popul myasthenia estim rang charl martineau pm univers toronto novemb
believ fcrn antagonist class compet potenti replac ivig util
subset indic wouldnt expect complet switch across indic ivig
sever potenti mechan action across indic satur fcrn
one
figur potenti immunomodulatori mechan ivig
adapt nagelkerk siets kuijper immunomodul ivig role
fc-gamma receptor classic mechan action frontier immunolog
addit indic replac ivig fcrn antagonist
doesnt make mechanist rational one greater support fcrn
antagonist could advantag ivig
pid iv/sc ig market size cidp activ fcr satur via high-dos ivig make less avail auto-antibodi oligo- polymer complex upregul inhibitori fcriib sialyl igg increas clearanc pathogen antibodi satur neonat fcr tip cellular balanc pro- anti-inflammatori reactiv modul dendrit cell reduc respons inhibit complement cascad sequest complement away deposit auto-antibodiesfab-medi variou agent similar mab includ chemokin inflammatori cytokin apoptosis-induc molecul includ neutral auto-antibodi anti-idiotyp ab often claim never proven effect explain anti-inflammatori charl martineau pm univers toronto novemb
typic ivig treatment cycl day infus time per day
believ igg-driven autoimmun diseas current manag
ivig/plex low-hang fruit class see clinic develop pathway
potenti de-risk think overal valu proposit fcrn antagonist especi at-
home sc formul success develop offer compel profil share
gain/switch could open path convers opportun alon potenti
upsid broader util addit indic
select develop fundament optim
fcrn antagonist establish proof-of-concept human across gener myasthenia
gravi gmg idiopath thrombocytopen purpura itp pemphigu vulgari pv warm
autoimmun hemolyt anemia waiha ongoing/plan trial chronic inflammatori
demyelin polyneuropathi cidp hemolyt diseas fetu newborn grave
certainli potenti fcrn antagonist address multitud autoimmun
indic diseas like commerci viabl and/or support similar price
point point address player develop differ formul
drug candid
argx product develop strategi focus opportun orphan potenti
econom viabl effici clinical/regulatori pathway compani current
three key therapeut area neuromuscular hematolog blister diseas
anchor indic expans possibl
neuromuscular lead indic myasthenia gravi current studi
cidp expect start hematolog diseas immun thrombocytopenia
lead indic pemphigu vulgari mark third beachhead indic
well-establish clinic practicelong-term safeti establish posit efficaci poc sever mechan actionsingl mechan actionodos regimen may cumbersom potenti improv dose regimenohuman plasma deriv supply/qu issu paststandard biolog manufactur processfcrn antagonismivig/scig charl martineau pm univers toronto novemb
mgadult itppvcidpu achr musk target membran glycoproteinsdsg /- entir character portion patient confirm igg autoantibodiesmechan diseasenmj impairment/damag block achr cross-link intern complement recruitmentdecreas platelet productionincreas platelet clearanceinduc platelet destructionautoantibodi lead loss desmosom drive loss cohes keratinocyt epidermisdestruct nerv myelin sheat multipl potenti caus standard careacetylcholinesteras inhibitorsteroidsimmunosupressantsivig inhibitorrituximabsteroidsimmunosupressantsivigtpo-mimeticsrituximabsyk inhibitorsteroidsrituximabimmunosupressantsivigivigsteroidspleximmunosupressantscompanyproducttri indicationsidentifiernstatusargenxefgartigimod gmg result expect sc -- cidp data expect volunt sc data expect volunt result result updat sc -plan volunt sc -waiha sad/mad data expect interim top-line data readout expect readout expect end readout expect result expect ophthalmopathi result expect ophthalmopathi result expect sc plan result expect charl martineau pm univers toronto novemb
clear path becom integr player
argenx recent outlin clear commerci strategi support initi two franchis
neuromuscular hematology/oncolog compani intend self-commerci
efgartigimod wholly-own asset us europ japan
goal five launch five year start expect efgartigimod launch
figur franchis clear expans opportun
unknown potenti product profil owe competit dynam
player fcrn space limit disclosur indic final
